Onkologie. 2023:17(5):353-356 | DOI: 10.36290/xon.2023.066

Adjuvant treatment for colorectal cancer

Marián Liberko, Renata Soumarová
Onkologická klinika, 3. LF UK a FNKV, Praha
3. lékařská fakulta, Karlova univerzita, Praha

Adjuvant treatment aims to decrease risk of recurrence and prolong overal survival across malignancies. In stage II colorectal cancer patients, it is important to discuss option for adjuvant treatment with patient, because of limited benefit in general population. On the other hand, adjuvant treatment is long-term standard for patients with stage III disease. In the last few years, there is a trend to individualize treatment based on presence of risk factors. Review summarize up-to-date guidelines for adjuvant treatment in stage II and III colorectal cancer patients.

Keywords: adjuvant chemotherapy, colorectal cancer, stage II, stage III.

Accepted: November 28, 2023; Published: November 29, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. Adjuvant treatment for colorectal cancer. Onkologie. 2023;17(5):353-356. doi: 10.36290/xon.2023.066.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020;70(4):313. PMID: 30207593. Go to original source... Go to PubMed...
    2. Gunderson LL, Jessup JM, Sargent DJ, et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264-271. doi: 10.1200/JCO.2009.24.0952. Epub 2009 Nov 30. PMID: 19949014; PMCID: PMC2815715. Go to original source... Go to PubMed...
    3. Argilés G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291-1305. doi: 10.1016/j.annonc.2020.06.022. Epub 2020 Jul 20. PMID: 32702383. Go to original source... Go to PubMed...
    4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420-1425. doi: 10.1093/jnci/djh275. PMID: 15467030. Go to original source... Go to PubMed...
    5. Swanson RS, Compton CC, Stewart AK, et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003;10(1):65-71. doi: 10.1245/aso.2003.03.058. PMID: 12513963. Go to original source... Go to PubMed...
    6. Quah HM, Chou JF, Gonen M, et al. Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum. 2008;51(5):503-507. doi: 10.1007/s10350-008-9246-z. Epub 2008 Mar 6. PMID: 18322753. Go to original source... Go to PubMed...
    7. Michelassi F, Ayala JJ, Balestracci T, et al. Verification of a new clinicopathologic staging system for colorectal adenocarcinoma. Ann Surg. 1991;214(1):11-8. doi: 10.1097/00000658-199107000-00003. PMID: 2064465; PMCID: PMC1358408. Go to original source... Go to PubMed...
    8. Yun JA, Kim HC, Kim SH, et al. Prognostic significance of perineural invasion in stage IIA colon cancer. ANZ J Surg. 2016;86(12):1007-1013. doi: 10.1111/ans.12810. Epub 2014 Aug 12. PMID: 25113398. Go to original source... Go to PubMed...
    9. Dienstmann R, Mason MJ, Sinicrope FA, et al. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study. Ann Oncol. 2017;28(5):1023-1031. doi: 10.1093/annonc/mdx052. PMID: 28453697; PMCID: PMC5406760. Go to original source... Go to PubMed...
    10. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol. 1999;17(5):1356-63. PMID: 10334519.
    11. Quasar Collaborative Group; Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020-2029. doi: 10.1016/S0140-6736(07)61866-2. PMID: 18083404. Go to original source... Go to PubMed...
    12. Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872-877. doi: 10.1200/JCO.2008.19.5362. Epub 2009 Jan 5. PMID: 19124803; PMCID: PMC2738431. Go to original source... Go to PubMed...
    13. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768-3774. doi: 10.1200/JCO.2011.36.4539. Epub 2011 Aug 22. PMID: 21859995; PMCID: PMC3188282. Go to original source... Go to PubMed...
    14. André T, de Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015;33(35):4176-4187. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2. PMID: 26527776. Go to original source... Go to PubMed...
    15. Grothey A, Sobrero AF, Shields AF, Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018;378(13):1177-1188. doi: 10.1056/NEJMoa1713709. PMID: 29590544; PMCID: PMC6426127. Go to original source... Go to PubMed...
    16. Iveson TJ, Sobrero AF, Yoshino T, et al. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. J Clin Oncol. 2021;39(6):631-641. doi: 10.1200/JCO.20.01330. Epub 2021 Jan 13. Erratum in: J Clin Oncol. 2021 May 20;39(15):1691. PMID: 33439695; PMCID: PMC8078416. Go to original source... Go to PubMed...
    17. Taieb J, André T, Auclin E. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. Cancer Treat Rev. 2019;75:1-11. doi: 10.1016/j.ctrv.2019.02.002. Epub 2019 Feb 26. PMID: 30849607. Go to original source... Go to PubMed...
    18. André T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351. doi: 10.1056/NEJMoa032709. PMID: 15175436. Go to original source... Go to PubMed...
    19. Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29(1):11-16. doi: 10.1200/JCO.2010.30.0855. Epub 2010 Oct 12. PMID: 20940184; PMCID: PMC3055856. Go to original source... Go to PubMed...
    20. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383-1393. doi: 10.1001/jama.2012.385. PMID: 22474202; PMCID: PMC3442260. Go to original source... Go to PubMed...
    21. André T, Meyerhardt J, Iveson T, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21(12):1620-1629. doi: 10.1016/S1470-2045(20)30527-1. PMID: 33271092; PMCID: PMC7786835. Go to original source... Go to PubMed...
    22. Gallois C, Shi Q, Meyers JP, et al. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2023;41(4):803-815. doi: 10.1200/JCO.21.02726. Epub 2022 Oct 28. PMID: 36306483. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.